ELIQUIS: payments to doctors
Payments that named ELIQUIS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $28.3M
- Providers
- 142,788
- Transactions
- 999,577
- Average per transaction
- $28
The per-transaction average — $28 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 142,788 providers the average total is $198, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pfizer | $17,753,089 | 62.7% |
| E.r. Squibb & Sons, L.L.C. | $10,339,156 | 36.5% |
| PBG Puerto RICO LLC | $128,229 | 0.5% |
| Pfizer Pharmaceuticals LLC | $88,738 | 0.3% |
| Pfizer S.a.s. | $5,950 | 0.0% |
| Bristol Myers Squibb | $3,906 | 0.0% |
| PBG Puerto Rico LLC | $17 | 0.0% |